Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Mipletamig, RUO) (HB714126)

Name: Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Mipletamig, RUO)
Brand: abinScience
SKU: HB714126
Price: 220 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HB714126

Descripción

Mipletamig (HB714126) is a research-grade recombinant antibody targeting CD123. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Reactividad de especies

Human

Aplicaciones

ELISA, Bioactivity: FACS, Functional assay, Research in vivo, WB

Especie huésped

Human

Clonalidad

Monoclonal

Isotipo

Immunoglobulin IG chain scFvkh-G1hCH2CH3-scFvhk dimer bisdisulfide

Sistema de expresión

Mammalian cells

Aplicaciones probadas

Objetivo

IL-3R subunit alpha, IL-3 receptor subunit alpha, CD123, Interleukin-3 receptor subunit alpha, IL3R, IL-3R-alpha, IL3RA, IL-3RA, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain

Nivel de endotoxinas

< 10 EU/mg

Pureza

>95% purity as determined by SDS-PAGE.

Purificación

Protein A/G purified from cell culture supernatant.

Número de acceso

P26951 & P07766

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
WB	1:500-1:2000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Nombres alternativos

Bispecific, Tetravalent, 2839556-21-5

Fondo

Vibecotamab (XmAb®14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.

Nota

For research use only. Not suitable for clinical or therapeutic use.

Isotype Control

Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)

Imágenes

SDS-PAGE

SDS-PAGE for Research Grade Mipletamig.
Western blot

Western blot analysis was performed using anti-IL3RA monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human IL3RA (Catalog No: HB714021)
Lane 2: recombinant human CD3E (Catalog No: HY057021)